Journal of Nanobiotechnology · 2021 · 26 citations · 38 references
MedicineOncologyPharmacologyCancer PharmacologyDrug DiscoveryMolecular PharmacologyAnti-inflammatory PharmacologyAnticancer Prodrug DesignColorectal CancerGastrointestinal Cancer PharmacotherapyInflammatory Bowel DiseaseUlcerative Colitis PharmacotherapyAnti-inflammatory ActivityAnti-inflammatory MechanismsAnti-inflammatory TherapeuticsCyclodextrin Inclusion ComplexesFolate ChemistryInflammatory Bowel Disease TherapyTumor Suppression Mechanisms
BACKGROUND: There is an obvious correlation between ulcerative colitis and colorectal cancer, and the risk of colorectal cancer in patients with ulcerative colitis is increasing. Therefore, the combination therapy of anti-inflammatory and anti-tumor drugs may show promising to inhibit colon cancer. 5-aminosalicylic acid (5-ASA) with anti-inflammatory function is effective for maintaining remission in patients with ulcerative colitis and may also reduce colorectal cancer risk. Histone deacetylase (HDAC) plays an essential role in the progression of colon cancer. Butyric acid (BA) is a kind of HDAC inhibitor and thus shows tumor suppression to colon cancer. However, the volatile and corrosive nature of BA presents challenges in practical application. In addition, its clinical application is limited due to its non-targeting ability and low bioavailability. We aimed to synthesize a novel dual-prodrug of 5-ASA and BA, referred as BBA, to synergistically inhibit colon cancer. Further, based on the fact that folate receptor (FR) is over-expressed in most solid tumors and it has been identified to be a cancer stem cell surface marker in colon cancer, we took folate as the targeting ligand and used carboxymethyl-β-cyclodextrin (CM-β-CD) to carry BBA and thus prepared a novel inclusion complex of BBA/FA-PEG-CM-β-CD. RESULTS: It was found that BBA/FA-PEG-CM-β-CD showed significant inhibition in cell proliferation against colon cancer cells SW620. It showed a pro-longed in vivo circulation and mainly accumulated in tumor tissue. More importantly, BBA/FA-PEG-CM-β-CD gave great tumor suppression effect against nude mice bearing SW620 xenografts. CONCLUSIONS: Therefore, BBA/FA-PEG-CM-β-CD may have clinical potential in colon cancer therapy.
38
Rebecca L. Siegel, Deepa Naishadham, Ahmedin Jemal · CA A Cancer Journal for Clinicians · 2012 · 10.7K citations · Full text
Identification and expansion of human colon-cancer-initiating cells
Lucia Ricci‐Vitiani, Dario Lombardi, Emanuela Pilozzi et al. · Nature · 2006 · 4K citations
Medicine, Cancer Biology, Oncology +12
Dong Hyun Sinn, Jeong Kim, Su Rin Shin et al. · Hepatogastroenterology · 2011 · 663 citations
George P. Kim, Linda H. Colangelo, H. Samuel Wieand et al. · Journal of Clinical Oncology · 2007 · 343 citations · Full text
Medicine, Cancer Biology, Oncology +17
Gold nanoparticle sensitize radiotherapy of prostate cancer cells by regulation of the cell cycle
Wilson Roa, Xiaojing Zhang, Linghong Guo et al. · Nanotechnology · 2009 · 315 citations
Medicine, Cell Biology, Oncology +17